Skip to NavigationSkip to content

Catalyst's lead candidate Firdapse falls short in Congenital Myasthenic Syndromes

Published on 31/10/19 at 12:51pm

Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS) in patients over the age of two years old.

In what was the first trial of its kind in genetically confirmed CMS patients, individual patient improvements were observed but ultimately meet its goal of subject global impression – the study’s primary endpoint – or its secondary endpoint of muscle function measure, across all tested subtypes.

The news means the end of a study that, due to the rarity of the condition, took four years to recruit for. Firdapse is already approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), and is currently being assessed in other CMS, neuromuscular and neurological diseases

“While we are disappointed that this trial did not reach its primary or secondary endpoints in the evaluated CMS patient subtypes, we are pleased with the new valuable clinical information that these results will provide to the medical and scientific communities as we work to develop FDA-approved treatment options for patients with this disease” said Patrick J McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “We also remain committed to developing FDA-approved treatment options for other rare neuromuscular disorders.”

Dr Steven Miller, Chief Operating Officer and Chief Scientific Officer of Catalyst, added: “We have made significant progress in genetically testing patients who were unable to previously get diagnosed. Due to the small patient prevalence, the low number of patients tested, and heterogeneity of the disease with a wide range of variation in clinical presentation across its more than 50 subtypes, it was challenging to demonstrate a statistically significant benefit across multiple subtypes.”

The company will now meet with the FDA in light of the results to determine a path forward for securing regulatory approval for Firdapse.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches